Tyme Technologies, Inc. (TYME)

Trade Setup

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.

Stocks found in this category are low priced stocks priced between .50 and $1, with at least 50k shares of average shares trading per day.   The stocks are pausing a trend either up or down, with a new bar over the prior day open or close.  These are high reward to risk stocks with the potential for very sharp moves.  A stop should be maintained at the low of the prior day.   Target prices for exits can be determined by using the next level of resistance higher or by using Fibonacci resistance levels found using TradersPro.

X